Adana, Turkey

Seyda Erdogan


Average Co-Inventor Count = 2.0

ph-index = 2

Forward Citations = 80(Granted Patents)


Company Filing History:


Years Active: 2009-2010

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Seyda Erdogan: Innovator in Renal Cancer Prognosis

Introduction

Seyda Erdogan is a notable inventor based in Adana, Turkey. He has made significant contributions to the field of medical diagnostics, particularly in the prognosis of renal cell carcinoma. With two patents to his name, his work focuses on improving patient outcomes through innovative methods.

Latest Patents

Erdogan's latest patents include MN/CA IX/CA9 and renal cancer prognosis. These patents disclose methods that are prognostic for renal cell carcinoma, especially renal clear cell carcinoma, affecting vertebrates. An exemplary prognostic method involves detecting the presence and quantifying the level of MN/CA9 gene expression products in samples from affected subjects. If 50% or fewer cells express the MN/CA9 gene, the subject is considered to have a poorer prognosis. The MN/CA9 gene expression products useful in these methods include MN protein, MN polypeptide, and MN nucleic acids. These methods aid in selecting treatment for patients with renal cell carcinoma, either alone or in combination with conventional tumor stage and grade information. They can identify patients requiring more aggressive therapy regimens or those most likely to respond to MN/CA IX/CA9-targeted therapies.

Career Highlights

Erdogan has worked at prominent institutions, including the Institute of Virology Slovak Academy of Sciences and the Institute of Virology of the Slovak Academy of Sciences. His experience in these research institutions has contributed to his expertise in the field of virology and cancer prognosis.

Collaborations

Erdogan has collaborated with Bülent Soyupak, a fellow researcher in his field. Their partnership has likely enhanced the development of innovative methods for cancer prognosis.

Conclusion

Seyda Erdogan's contributions to renal cancer prognosis through his patents and research collaborations highlight his commitment to improving patient care. His innovative methods have the potential to significantly impact treatment strategies for renal cell carcinoma.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…